MELAS-KPI

The overarching goal of this project is the development of specific and reliable biomarkers for improved patient stratification and tumor classification, and the understanding of the mechanisms responsible for therapy resistance, in particular for drugs in development in Novartis through the integrative analysis of clinical, images of hematoxilin and eosin stained tissue sections, and multiomics data (bulk RNA-sequencing, 10X Genomics single-cell sequencing, Smart-seq 3 full-length single-cell sequencing data, spatial transcriptomics).